

File 6013-149US MHR/kb

Montreal, Canada  
March 30, 2007

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Philippe A. TESSIER  
Serial Number : 10/517,319  
Filed : July 15, 2005  
Title: CHEMOTACTIC FACTOR INHIBITOR FOR MODULATING INFLAMMATORY REACTIONS  
Art Unit : 1656  
Examiner : Marsha M. TSAY  
Agent of Record : Marie-Hélène ROCHON  
Telephone number : (514) 847-6095

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450  
U.S.A

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97**

Sir:

Submitted herewith on a PTO/SB/08b form is a listing of the documents known to applicant in order to comply with applicant's duty of disclosure pursuant to 37 C.F.R. § 1.56.

The submission of any document which is not a statutory bar is not intended as an admission that such document constitutes prior art against the claims of the present application. Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

**Statement of Relevancy**

The listed document is being submitted either in compliance with 37 C.F.R. §1.97(b), within three (3) months of the filing date of a national application or of the date of entry of the national stage in an international application; or pursuant to 37 C.F.R. §1.97(e)(1), within three (3) months from the date of an office action or of a search report issued in a foreign counterpart application citing each of the documents contained in the present statement; or pursuant to 37 C.F.R. §1.97(e)(2), within three (3) months from the first knowledge of each submitted document by any individual designated in C.F.R. §1.56(c), when each such document was not cited in a communication from a foreign patent office in a counterpart foreign application.

In the case of submission under 37 C.F.R. §1.97(e)(1) and (2), the undersigned Attorney/Agent of Record hereby certifies that the enclosed list of references is hereby submitted within three months (1) from the issuance of the foreign action or search report, or (2) from said first knowledge, respectively.

The Examiner is kindly requested to consider these references during the examination of the above-identified application, making the references of record, and to return an initialed copy of the PTO/SB/08b Form to the below-signed agent.

Respectfully submitted,

Philippe A. TESSIER

By:



Marie-Hélène Rochon  
Registration No. 57,566  
Suite 1600 - 1981 McGill College Avenue  
Montreal, Québec, Canada H3A 2Y3  
Tel.: (514) 847-6095

Enclosure

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/517,319
		Filing Date	July 15, 2005
		First Named Inventor	Philippe A. TESSIER
		Art Unit	1656
		Examiner Name	TSAY, Marsha M
Sheet	1	of	1
		Attorney Docket Number	
		6013-149US	

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		EUE et al., Transendothelial migration of 27E10+ human monocytes, International Immunology, 2000, Vol. 12: 1593-1604	
		HARRISON et al., Oxidation Regulates the Inflammatory Properties of the Murine S100 Protein S100A8, The Journal of Biological Chemistry, 1999, Vol.274: 8561-8569	
		NEWTON et al., The Human S100 Protein MRP-14 Is a Novel Activator of the $\beta 2$ Integrin Mac-1 on Neutrophils, The Journal of Immunology, 1998, 160: 1427-1435	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.